Patricia Inácio, PhD,  science writer—

In a 39-year-old man in France, hereditary angioedema (HAE) manifested with stroke-like symptoms, including weakness on one side of the body and difficulty speaking, despite treatment with danazol, a medication normally used to prevent HAE attacks. His symptoms eventually resolved with Takhzyro (lanadelumab), an approved therapy for…

Long-term use of attenuated androgens — male hormones used as a preventive treatment — may increase the risk for other disorders in hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE), a retrospective analysis suggests. Disorders linked with their use included high blood pressure, high cholesterol, diabetes, and benign liver tumors. “The results…

Adding a short-term regimen of C1-INH concentrate to the preventive treatment of a 63-year-old man with hereditary angioedema (HAE) enabled a successful tooth extraction without a swelling attack in his larynx, a case study reports. The tailored Orladeyo (berotralstat) prophylaxis regimen was designed to prevent an attack…

A single subcutaneous or under-the-skin injection of STAR-0215 — an experimental treatment that aims to prevent swelling attacks in people with hereditary angioedema (HAE) — led to a sustained decrease in kallikrein protein activity in healthy adults for close to three months, according to new trial data. Early…

Treatment with rituximab — approved for certain cancers to reduce the levels of antibody-producing immune cells — is effective to control swelling attacks in people with acquired angioedema, particularly in cases where the disease is linked to an underlying lymphoma, or a blood cancer that develops in the lymphatic…

Women with hereditary angioedema (HAE) see an increase in the number and severity of disease attacks during pregnancy and while breastfeeding, according to a study in Turkey. A normal vaginal delivery without anesthesia was associated with a lower attack rate, leading researchers to argue that in the absence of  “special…

Pharvaris has completed patient enrollment for its proof-of-concept CHAPTER-1 clinical trial that will evaluate the safety and effectiveness of deucrictibant as a prophylactic, or preventive, treatment for adults with hereditary angioedema (HAE). While the global Phase 2 CHAPTER-1 study (NCT05047185) is still on hold in the U.S.,…

Enrollment for the Phase 2 portion of a clinical trial testing NTLA-2002, Intellia Therapeutics’ experimental gene-editing therapy for hereditary angioedema (HAE), is expected to be completed this year. This is the result of “substantial interest from physicians and patients to participate in the NTLA-2002 clinical program,” the company…

A 26-year-old woman developed a rare case of non-episodic angioedema associated with eosinophilia (NEAE) following her second dose of the Pfizer-BioNTech COVID-19 vaccine, according to a study from Japan. Eosinophilia refers to higher-than-normal levels of a type of immune cells called eosinophils. Her NEAE symptoms were resolved completely two months…

The use of Dupixent (dupilumab), an approved treatment for skin and respiratory conditions linked to a specific type of inflammation, led to the development of angioedema in a woman in her 40s, as described in a new case report from U.S. researchers. The woman, who had a type…